Erasca (ERAS) Reaches 4-Year High Ahead of ERAS-0015 Trial Results
Erasca (NASDAQ:ERAS) reached a four-year high as investors anticipated the results of its ERAS-0015 clinical trial for pancreatic cancer treatment. The stock surged 14.20% to $21.71, with year-to-date gains of 483.6%. Positive data from early trials and expanded rights in Asia have fueled investor optimism.
Topics: clinical trial results market optimism pharmaceutical development stock price movement